Indication name: Crohn’s
disease
Crohn’s disease (CD) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019
To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy,
Japan & China)
Crohn’s disease is an
inflammatory bowel disease (IBD) that causes chronic inflammation of the
gastrointestinal tract. Recent research suggests hereditary, genetic, and
environmental factors contribute to Crohn’s disease development. Men and women
are equally likely to be affected. The disease can occur at any age, but
Crohn’s disease is most prevalent in adolescents and adults between the ages of
15 and 35. Diet and stress may aggravate Crohn’s disease, but do not cause the
disease.
Thelansis estimated that there were
1,721,731 prevalent patients suffering from Crohn’s disease in the US alone.
China has relatively (177 times less than the US) very less diagnosed
prevalence of CD. In Europe, the prevalence was estimated to be ~800,000 in
2018 while in Japan it was reported to be ~50,000.
Competitive landscape of Crohn’s
disease (CD) includes country specific approved as well as pipeline therapies.
Any asset/ product specific designation or review and Accelerated Approval are
being tracked and supplemented with analyst commentary.
With the availability of newer
therapeutic options like Remicade, Humira, Cimzia etc. the long term prognosis
of the disease has improved a little. In clinical pipeline, biosimilar versions
of Humira are set to enter the market followed by promising molecules like
upadacitinib (Abbvie) and filgotinib (Galapagos). Steroid dependence in
Moderate to Severe CD is a challenge that newer treatment options are trying to
eliminate.
Biologics manufacturers are
looking at improving their formulary positioning through contracting strategies
in the US.
KOLs
insights of Crohn’s disease (CD) across 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Crohn’s disease (CD) Market
Forecasting: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden and pricing scenario,
Summary and Insights.
S. No Asset Company Stage
1 Kromeya (adalimumab) Fresenius Kabi Filed
2 RHB-104 RedHill Biopharma III
3 Etrolizumab Roche III
4 Rifaximin DR Valeant Pharma III
5 Filgotinib Galapagos and Gilead III
6 Risankizumab Abbvie and BI III
7 Upadacitinib Abbvie III
8 SHP-647 Shire III
9 Ozanimod Celgene III
10 Brazikumab Allergan III
11 guselkumab Janssen Biotech III
12 Etrasimod Arena Pharmaceuticals III
13 JNJ-64304500 J&J II
14 Amiselimod Mitsubishi II
15 Mirikizumab Eli Lilly II
16 E6011 (Quetmolimab) Eisai II
17 Alequel Enzo Biochem II
18 BMS-986165 BMS II
19 Foralumab (TZLS-401) Tiziana Life sciences II
20 PF-06651600 Pfizer II
21 PF-06700841 Pfizer II
22 Edicotinib (PRV-6527) Provention Bio / Jansenn II
23 TD-1473 Theravance Biopharma / Janssen II
24 V-565 VHsquared II
25 QBECO Qu Biologics II
26 OPS-2071 Otsuka Pharmaceutical II
27 ABX464 Abivax S.A. II
28 SHR0302 Reistone Biopharma II
29 RG-7880/UTTR1147A Genentech II
30 EcoActive Intralytix II
31 EB 8018 Enterome Bioscience II
32 FFP104 Fast Forward Pharma I
33 FURESTEM-CD Kang Stem Biotech I
34 AD-cSVF Healeon I
35 AEVI-002 Aevi Genomics / KHK I
36 alicaforsen sodium Atlantic Healthcare I
No comments:
Post a Comment